Pfizer Inc. $PFE Shares Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 868,327 shares of the biopharmaceutical company’s stock after buying an additional 39,989 shares during the quarter. Advisors Asset Management Inc.’s holdings in Pfizer were worth $22,125,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. Lion Street Advisors LLC boosted its holdings in shares of Pfizer by 6.8% in the second quarter. Lion Street Advisors LLC now owns 10,381 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 660 shares during the period. Vest Financial LLC grew its position in shares of Pfizer by 39.5% during the second quarter. Vest Financial LLC now owns 65,904 shares of the biopharmaceutical company’s stock worth $1,598,000 after acquiring an additional 18,652 shares during the last quarter. Finally, NorthRock Partners LLC increased its holdings in shares of Pfizer by 37.9% in the 2nd quarter. NorthRock Partners LLC now owns 66,651 shares of the biopharmaceutical company’s stock valued at $1,616,000 after acquiring an additional 18,323 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. HSBC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Finally, Bank of America decreased their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.06.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants priority review for HYMPAVZI (marstacimab) sBLA — a near-term regulatory catalyst that could speed approval and future revenue potential if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Pfizer to collect $29M from an SEC settlement tied to the 2013 SAC Capital matter — a small but tidy legal recovery that removes uncertainty and adds cash. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Positive Sentiment: Pfizer India reports strong Q3FY26 results (profit +11%, revenue +20%), signaling healthy regional execution and bolstering sentiment among EM investors. Pfizer shares gain 9% after Q3FY26 profit up 11%, revenue grows 20%
• Neutral Sentiment: Analyst takeaways from the Q4 call: Pfizer beat EPS and revenue estimates but reported weak COVID-related sales and provided cautious 2026 commentary — investors are parsing how much the pipeline and partnerships can offset near-term headwinds. 5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
• Neutral Sentiment: Pfizer is a trending / widely watched stock; commentary focuses on income appeal (high yield) vs. growth uncertainty — useful for income investors but not a decisive growth thesis. Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Analysis flags that pipeline progress and partnerships are being judged against a depressed valuation — investors remain skeptical about whether collaboration deals and late-stage assets will justify current multiples. Pfizer Pipeline Progress And Partnerships Tested Against Depressed Valuation
• Negative Sentiment: Independent analyst coverage warns of an approaching patent cliff and the need for a standout obesity franchise — risks that could pressure long-term growth absent clear pipeline wins. Pfizer: ‘Hold’ As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Pfizer Stock Performance

NYSE PFE opened at $27.61 on Wednesday. The stock has a market capitalization of $156.98 billion, a price-to-earnings ratio of 20.30 and a beta of 0.47. The business’s 50 day moving average is $25.70 and its two-hundred day moving average is $25.13. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.73. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the business earned $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.